CardioTarget: Development of targeted therapies for HFpEF

Heart failure with preserved ejection fraction (HFpEF) is a disease currently with few to noen therapies proven to be life prolonging despite high mortality and worldwide disease burden. The lack of a system-based model of HFpEF and its upstream, causal drivers clearly hinders identification of targeted therapies. Here we want to take full advantage of two technical breakthroughs from our project group to obtain deep phenotyping with multi-omics data at multiple time point from the very beginning to fully developed disease. We are confident that this approach, that we name temporal pheno-omics, will allow us to identify upstream, causal factors that drives disease development as the first output of the project. Identification of such targets are vital in the effort to develop targeted therapies for this disease, and as a second outcome of this project we will alidate whether two targets we earlier have identified modulates the upstream, causal drivers by the same approach. Based on the outcome of these studies, in combination with search for strategies to modulate upstream nodes by repurposing of existing drugs, we aim to secure translation of the overall results from this project in in future studies.

Heart failure with preserved ejection fraction (HFpEF) is a disease currently with few to none therapies proven to be life prolonging despite high mortality and worldwide disease burden. The lack of a system-based model of HFpEF and its upstream, causal drivers clearly hinders identification of targeted therapies. Here we want to take full advantage of two technical breakthroughs from our project group to obtain deep phenotyping with multi-omics data at multiple time point from the very beginning to fully developed disease. We are confident that this approach, that we name temporal pheno-omics, will allow us to identify upstream, causal factors that drives disease development as the first output of the project. We will validate whether two targets we earlier have identified modulates the upstream, causal drivers by the same approach. Based on the outcome of these studies, in combination with search for strategies to modulate upstream nodes by repurposing of existing drugs, we aim to secure translation of the overall results from this project in in future preclinical studies. Our proven track record, including earlier identification of molecular targets, securing IPR and ongoing project in the institutional TTO to further qualify our earlier findings for clinical testing, demonstrates the potential of the project team to secure the goals of this ambitious project.